On November 5, 2020 DCprime, the front-runner in the field of relapse vaccines, reported the upcoming oral presentation of interim results from its ongoing Phase II clinical trial (ADVANCE II, Clintrials.gov: NCT03697707) at the virtual 62nd ASH (Free ASH Whitepaper) Annual Meeting and Exposition on December 5, 2020 (Press release, DCPrime, NOV 5, 2020, View Source [SID1234570041]). The Interim data on both primary and secondary endpoints of the trial highlight the potential of the company’s lead vaccine candidate, DCP-001, to improve the treatment options for patients with Acute Myeloid Leukemia (AML) in the post-remission setting. The study continues to enroll patients at the higher of two vaccine doses tested and updated data will be shown at ASH (Free ASH Whitepaper).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The oral presentation entitled "Conversion from MRD positive to negative status in AML patients in CR1 after treatment with an Allogeneic Leukemia-derived Dendritic Cell Vaccine" will be presented by Prof. Dr. Arjan van de Loosdrecht from the Department of Hematology at Amsterdam UMC, Amsterdam, The Netherlands, and Principal Investigator for the study.
The accepted abstract is listed below and is now available online on the ASH (Free ASH Whitepaper) website: View Source
ORAL PRESENTATION DETAILS:
Presentation Title: #168: Conversion from MRD positive to negative status in AML patients in CR1 after treatment with an Allogeneic Leukemia-derived Dendritic Cell Vaccine
Session Title: Acute Myeloid Leukemia: Novel therapy, excluding transplantation: Advances in immunotherapeutics for management of AML
Session Date: Saturday, December 5, 2020
Presentation Time: 12:45 PM EST
Presenter: Prof. Dr. Arjan van de Loosdrecht – Department of Hematology, VUmc